

COVID-19–Associated Hospitalizations Update – COVID-NET, July 2023–September 2024


Adults Ages ≥65 Years and Persons with Immunocompromising Conditions

Christopher A. Taylor, PhD RESP-NET Hospitalization Surveillance Team Coronavirus and Other Respiratory Viruses Division

Meeting of the Advisory Committee on Immunization Practices (ACIP) October 23, 2024

COVID-NET is a population-based hospitalization surveillance platform.

- RESP-NET: COVID-NET, RSV-NET, FluSurv-NET
- >300 acute-care hospitals
- 98 counties in 13 states
 - 90 counties in 12 states for this analysis due to incomplete data
- Approx. 10% of the U.S. population
- Positive SARS-CoV-2 test ≤14 days before admission or during hospitalization
- Screening or clinician-driven testing
- Clinical data: stratified random sample







COVID-19–Associated Hospitalizations Among Adults Ages ≥65 Years

Adults ages ≥65 years comprise 2/3 of all COVID-19– associated hospitalizations among adults.


Percent of weekly COVID-19–associated hospitalizations, by age group — COVID-NET, March 2020-September 2024



Rates of COVID-19 hospitalizations are highest among adults ages ≥75 years.



Among adults, rates of COVID-19–associated hospitalizations increase with age.



24.4


8.7

3.4

1.0

Rates of COVID-19–associated hospitalizations among adults ages ≥65 years have decreased over time.

Cumulative rates of COVID-19-associated hospitalizations - COVID-NET, March 2020-September 2024



* The 2019–2020 surveillance period includes March 2020–September 2021.

Most adults ages ≥65 years hospitalized with COVID-19 have underlying medical conditions.

- Among adults ages ≥65 years:
 - 19% are residents of a long-term care facility (LTCF)
 - 83% have \geq 2 underlying medical conditions.
- Among adults ages ≥75 years:
 - 24% are residents of a LTCF
 - 86% have ≥2 underlying conditions





Data are limited to hospitalizations where COVID-19 is a likely primary reason for admission during October 2023–May 2024.

Adults ages ≥65 years remain at risk for severe outcomes during COVID-19–associated hospitalization.


Percent of outcomes and interventions among COVID -19–associated hospitalizations, by age group — COVID-NET, October 2023–May 2024

	18–49	50-64	≥65
Length of stay, days (median)	2.9	3.4	3.5
Length of stay, days (IQR)	1.4–5.5	1.9–7.9	1.9–7.1
ICU admission	17.9%	21.5%	17.7%
Invasive mechanical ventilation	5.9%	12.8%	8.1%
In-hospital death	2.1%	11.3%	7.7%

During this period, 80% of all adults hospitalized with COVID-19 who died in-hospital were ages ≥65 years.

Fewer than half of adults ages ≥65 years hospitalized with COVID-19 received any COVID-19 vaccine since September 2022.

Vaccination status among adults with COVID -19–associated hospitalization, by age group — COVID-NET, October 2023–May 2024



No record of 2022–2023 (bivalent) or 2023–2024 formula

Received 2022–2023 (bivalent), but not 2023–2024 formula

Received 2023–2024 formula

COVID-19–Associated Hospitalizations Among Persons with Immunocompromising Conditions


Immunocompromising conditions among patients hospitalized with COVID-19 include:

- AIDS or CD4 count <200
- Complement deficiency
- Graft vs. host disease
- HIV infection
- Immunoglobulin deficiency
- Immunosuppressive therapy*
- Leukemia**
- Lymphoma**
- Malignancy (solid organ)**
- * Within the 12 months before admission
- ** Current/in treatment or diagnosed in the 12 months before admission
- *** Within 2 weeks before admission. Does not include inhaled, intranasal steroids or intramuscular or intra-articular injection of steroids.

- Bone marrow transplant
- Metastatic cancer**
- Multiple myeloma**
- Steroid therapy***
- Solid organ transplant
- Other conditions typically associated with immunocompromised status upon review

About 1 in 6 (15.6%) persons hospitalized with COVID-19 have an immunocompromising condition.

Immunocompromising condition among persons with COVID -19-associated hospitalization, by age group — COVID-NET, July 2023-May 2024




Immunocompromising condition

■ No immunocompromising condition

The most common immunocompromising conditions among persons hospitalized with COVID-19 include:

Prevalence of immunocompromising conditions among persons hospitalized with COVID -19 with immunocompromised status — COVID-NET, July 2023-May 2024



* Within the 12 months before admission


** Current/in treatment or diagnosed in the 12 months before admission

*** Within 2 weeks before admission. Does not include inhaled, intranasal steroids or intramuscular or intra-articular injection of steroids.

Data are limited to hospitalizations where COVID-19 is a likely primary reason for admission.

Few persons with an immunocompromising condition hospitalized with COVID-19 received any COVID-19 vaccine since September 2022.

Vaccination status among persons hospitalized with COVID -19, by immunocompromising status — COVID-NET, October 2023-May 2024




Immunocompromising condition

■ No immunocompromising condition


Time since receipt of most recent COVID-19 vaccine varies little by immunocompromising condition status.

Time since receipt of most recent COVID-19 vaccine among persons hospitalized with COVID-19, by immunocompromising status — COVID-NET, October 2023–May 2024




Limited to persons hospitalized with COVID-19 who received either a 2022–2023 (bivalent) or 2023–2024 formula COVID-19 vaccine since September 1, 2022. Data are limited to hospitalizations where COVID-19 is a likely primary reason for admission.

Risk for severe outcomes during COVID-19–associated hospitalization among children and adolescents varies little by immunocompromising condition status.



Risk for severe outcomes during COVID-19–associated hospitalization among adults varies by immunocompromising condition status.



Questions

